ArriVent BioPharma (NASDAQ:AVBP – Free Report) had its price objective upped by HC Wainwright from $44.00 to $47.00 in a research note published on Monday morning, MarketBeat reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for ArriVent BioPharma’s Q3 2026 earnings at ($1.04) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.14) EPS, Q1 2027 earnings at ($1.11) EPS, Q2 2027 earnings at ($1.16) EPS, Q3 2027 earnings at ($1.04) EPS, Q4 2027 earnings at ($0.93) EPS and FY2027 earnings at ($4.24) EPS.
Other research analysts have also issued reports about the company. BTIG Research reissued a “buy” rating and issued a $42.00 price objective on shares of ArriVent BioPharma in a report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Friday, July 17th. Citigroup decreased their target price on ArriVent BioPharma from $43.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ArriVent BioPharma in a research report on Friday, May 22nd. Finally, Guggenheim reiterated a “buy” rating and issued a $45.00 price target on shares of ArriVent BioPharma in a report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $44.86.
Get Our Latest Report on ArriVent BioPharma
ArriVent BioPharma Price Performance
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.06). As a group, research analysts anticipate that ArriVent BioPharma will post -4.01 EPS for the current fiscal year.
Institutional Investors Weigh In On ArriVent BioPharma
Several hedge funds have recently added to or reduced their stakes in the business. Hhlr Advisors LTD. purchased a new position in shares of ArriVent BioPharma during the 2nd quarter valued at about $136,498,000. BlackRock Inc. purchased a new stake in shares of ArriVent BioPharma in the second quarter worth about $112,919,000. General Catalyst Group Management LLC purchased a new stake in shares of ArriVent BioPharma in the second quarter worth about $51,929,000. Vivo Capital LLC acquired a new stake in ArriVent BioPharma during the first quarter worth about $20,438,000. Finally, AIHC Capital Management Ltd acquired a new stake in ArriVent BioPharma during the fourth quarter worth about $12,973,000. 9.48% of the stock is owned by hedge funds and other institutional investors.
More ArriVent BioPharma News
Here are the key news stories impacting ArriVent BioPharma this week:
- Positive Sentiment: HC Wainwright maintained a Buy rating and a $47 price target for ArriVent BioPharma (AVBP), indicating confidence in the company’s long-term potential and significant potential upside. HC Wainwright Forecasts Strong Price Appreciation for ArriVent BioPharma Stock
- Neutral Sentiment: HC Wainwright expects continued losses through 2027, forecasting EPS of approximately ($1.11) in the first quarter, ($1.16) in the second quarter, ($1.04) in the third quarter and ($0.93) in the fourth quarter of 2027. The estimates suggest profitability remains several quarters away.
- Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS forecast to ($1.04) from ($0.96), its Q4 2026 forecast to ($1.07) from ($0.99), and its full-year 2026 forecast to ($4.14) from ($3.86). The downward revisions indicate analysts expect heavier losses than previously projected.
About ArriVent BioPharma
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.
Read More
- Five stocks we like better than ArriVent BioPharma
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
